Quarterly report pursuant to Section 13 or 15(d)

11. SEGMENT INFORMATION (Details)

v3.8.0.1
11. SEGMENT INFORMATION (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Product sales, net $ 5,591,210 $ 2,939,997 $ 13,437,233 $ 7,850,430
Gross profit 3,997,649 1,888,949 9,275,111 5,178,911
Gain on change in derivative liability 10,987 0 248,875 0
Royalty buy-out 0 0 (2,432,000) 0
Selling, general and administrative (4,311,078) (3,072,441) (11,513,560) (9,147,411)
Research and development (179,338) (396,238) (573,701) (879,598)
Operating (loss) income (481,780) (1,579,730) (4,995,275) (4,848,098)
Consumer Products [Member]        
Product sales, net 5,591,210 2,939,997 13,437,233 7,850,430
Gross profit 3,997,649 1,888,949 9,275,111 5,178,911
Gain on change in derivative liability 10,987   248,875  
Royalty buy-out     0  
Selling, general and administrative (4,259,725) (2,952,533) (11,312,687) (8,904,694)
Research and development (76,520) (292,738) (181,509) (658,817)
Operating (loss) income (327,609) (1,356,322) (1,970,210) (4,384,600)
Specialty Pharmaceuticals [Member]        
Product sales, net 0 0 0 0
Gross profit 0 0 0 0
Gain on change in derivative liability 0   0  
Royalty buy-out     (2,432,000)  
Selling, general and administrative (51,353) (119,908) (200,873) (242,717)
Research and development (102,818) (103,500) (392,192) (220,781)
Operating (loss) income $ (154,171) $ (223,408) $ (3,025,065) $ (463,498)